A PHASE II/III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP TRIAL TO EVALUATE SAFETY AND EFFICACY OF TIOTORPIUM INHALATION SOLUTION (2.5 µG AND 5µG) ADMINISTERED ONCE DAILY IN THE AFT...

Mise à jour : Il y a 4 ans
Référence : PER-077-12

A PHASE II/III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP TRIAL TO EVALUATE SAFETY AND EFFICACY OF TIOTORPIUM INHALATION SOLUTION (2.5 µG AND 5µG) ADMINISTERED ONCE DAILY IN THE AFTERNOON VIA RESPIMAT® INHALER FOR 12 WEEKS INPATIENTS 1 TO 5 YEARS OLD WITH PERSISTENT ASTHMA